Patents by Inventor Yixin Ai
Yixin Ai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11746110Abstract: Disclosed are alkynyl (hetero) aromatic ring compounds that inhibit protein tyrosine kinases, pharmaceutical compositions comprising same, preparations therefor and uses thereof. Specifically, disclosed are an alkynyl (hetero) aromatic ring compound represented by formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotope variant thereof. The disclosed compounds may be used in the treatment and/or prevention of diseases associated with protein tyrosine kinase, such as in preventing tumors.Type: GrantFiled: July 16, 2019Date of Patent: September 5, 2023Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
-
Publication number: 20220380375Abstract: Provided in the present invention are a substituted aromatic fused ring derivative, a composition comprising the compound, and the use thereof. The substituted aromatic fused ring derivative is a compound as shown as formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition of the present invention can be used to treat various protein tyrosine kinase-mediated diseases or conditions.Type: ApplicationFiled: March 18, 2022Publication date: December 1, 2022Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai, Huanyin Li
-
Patent number: 11358973Abstract: A di(hetero)aryl macrocyclic compound having an inhibitory effect on protein kinase activity, preparation and the use thereof. Specifically, disclosed are a di(hetero)aryl macrocyclic compound represented by formula (I), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug or an active metabolite thereof, a pharmaceutical composition comprising said compound and the derivative thereof, and methods of using the same, including methods of treating cancers, pain, neurological diseases, autoimmune diseases and inflammation.Type: GrantFiled: April 10, 2019Date of Patent: June 14, 2022Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Patent number: 11319317Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: November 16, 2020Date of Patent: May 3, 2022Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20220098204Abstract: Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.Type: ApplicationFiled: February 13, 2020Publication date: March 31, 2022Applicant: Shenzhen TargetRX, Inc.Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
-
Patent number: 11111233Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.Type: GrantFiled: January 24, 2019Date of Patent: September 7, 2021Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
-
Publication number: 20210269448Abstract: Disclosed are alkynyl (hetero) aromatic ring compounds that inhibit protein tyrosine kinases, pharmaceutical compositions comprising same, preparations therefor and uses thereof. Specifically, disclosed are an alkynyl (hetero) aromatic ring compound represented by formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotope variant thereof. The disclosed compounds may be used in the treatment and/or prevention of diseases associated with protein tyrosine kinase, such as in preventing tumors.Type: ApplicationFiled: July 16, 2019Publication date: September 2, 2021Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
-
Patent number: 11091462Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: January 19, 2018Date of Patent: August 17, 2021Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20210171517Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: ApplicationFiled: November 16, 2020Publication date: June 10, 2021Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20210171542Abstract: A di(hetero)aryl macrocyclic compound having an inhibitory effect on protein kinase activity, preparation therefor and the use thereof. Specifically, disclosed are a di(hetero)aryl macrocyclic compound represented by formula (I), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug or an active metabolite thereof a pharmaceutical composition comprising said compound and the derivative thereof, and methods for using same, including methods for treating cancers, pain, neurological diseases, autoimmune diseases and inflammation.Type: ApplicationFiled: April 10, 2019Publication date: June 10, 2021Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Patent number: 10875853Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: January 19, 2018Date of Patent: December 29, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20200377473Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.Type: ApplicationFiled: January 19, 2018Publication date: December 3, 2020Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan WANG, Jiuyang ZHAO, Yixin AI
-
Publication number: 20190382374Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.Type: ApplicationFiled: January 19, 2018Publication date: December 19, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan WANG, Jiuyang ZHAO, Yixin AI
-
Publication number: 20190375745Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs comprising an anti-tumour drug.Type: ApplicationFiled: January 19, 2018Publication date: December 12, 2019Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20190152954Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.Type: ApplicationFiled: January 24, 2019Publication date: May 23, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai